Introduction
Compliance with California’s Proposition 65 for the monitoring of lead (Pb) in calcium-based antacid medications and dietary supplements requires the analytical methodology to demonstrate detection limits below 0.05 µg/g in the solid material. The analytical capabilities of inductively coupled plasma mass spectrometry (ICP-MS) make it the most suitable technique for performing lead determinations at these low levels on a routine basis.
This work investigates the use of the NexION® ICP-MS system to determine lead in various antacids and dietary supplements for compliance with California’s Prop 65 for the monitoring of lead (Pb) in calcium-based antacid medications and dietary supplements.
Like what you're reading?
To view the full content, please answer a few questions.